



## Curriculum Vitae Formato Europeo

### Informazioni personali

Nome **Salvatore**

Cognome **Alfieri**

Struttura **Fondazione IRCCS Istituto Nazionale  
dei Tumori**

Indirizzo lavorativo **Via G. Venezian n. 1, 20133, Milano**

Nationalità **Italiana**

Data di nascita **28 Agosto 1982**

### Esperienze professionali

Date (dal – al) **01 Agosto 2019 ad oggi**

Occupazione o Posizione Lavorativa **Specialista in Oncologia (Dirigente Medico a tempo determinato) (S.C. Oncologia Medica 3 Tumori della Testa e del Collo, diretta dalla Prof. Lisa Licitra)**

Principali aree di competenza ricoperte **Oncologia Medica**

Nome e indirizzo del Datore di Lavoro **Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milano, Italia**

Principali attività **Gestione clinica e multidisciplinare dei pazienti con tumori maligni della testa e del collo;  
Gestione clinica dei pazienti con tumori cutanei (melanomi esclusi);**

**Ricerca clinica nel campo dei tumori maligni della testa e del collo e dei tumori cutanei (melanomi esclusi);**

Date (dal – al) **01 Gennaio 2014 al 31 Luglio 2019**

Occupazione o Posizione Lavorativa **Specialista in Oncologia (Collaborazione Libero-Professionale) (S.C. Oncologia Medica 3 Tumori della Testa e del Collo, diretta dalla Prof. Lisa Licitra)**

Principali aree di competenza ricoperte **Oncologia Medica**

Nome e indirizzo del Datore di Lavoro **Fondazione IRCCS Istituto Nazionale dei Tumori, via G. Venezian 1, 20133 Milan, Italy**

Principali attività **Gestione clinica e multidisciplinare dei pazienti con tumori maligni della testa e del collo;  
Gestione clinica dei pazienti con tumori cutanei (melanomi esclusi);  
Ricerca clinica nel campo dei tumori maligni della testa e del collo e dei tumori cutanei (melanomi esclusi);**

Date (dal – al) **01 Aprile 2013 al 31 Dicembre 2013**

Occupazione o Posizione Lavorativa **Assegnista di Ricerca in Oncologia Medica (Dipartimento di Oncologia Medica, diretto dal Prof. G. Tortora)**

|                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Principali aree di competenza ricoperte                                    | Oncologia Medica                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Nome e indirizzo del Datore di Lavoro                                      | A.O.U.I. Università degli Studi di Verona, Ospedale Policlinico G.B. Rossi, P.le L.A. Scuro, 10, Borgo Roma, Verona, Italia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Principali attività                                                        | Attività clinica (reparto, ambulatorio, day hospital). Attività clinica ambulatoriale dedicata principalmente ai pazienti con tumori maligni dell'apparato gastrointestinale e della testa e del collo.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Date (dal – al)                                                            | 01 Luglio 2012 al 31 Marzo 2013                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Occupazione o Posizione Lavorativa                                         | Borsista in Oncologia Medica (Unità di Ricerca Traslationale, diretta dal Dr. P.F. Ferrucci)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Principali aree di competenza ricoperte                                    | Oncologia Medica                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Nome e indirizzo del Datore di Lavoro                                      | Istituto Europeo di Oncologia (IEO), Via G. Ripamonti, 435, Milano, Italia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Principali attività                                                        | Gestione clinica dei pazienti affetti da melanoma e dagli altri tumori cutanei. Ricerca clinica e traslazionale nel campo del melanoma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| <b>Formazione</b>                                                          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Data                                                                       | 21 Marzo 2012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Titolo conseguito                                                          | Specializzazione in Oncologia Medica (cum laude)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Nome e tipo di organizzazione presso la quale è stato conseguito il titolo | Università degli Studi "Federico II" di Napoli, Italia<br>Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica<br>Unità di Oncologia Medica                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Livello in classificazione nazionale o internazionale                      | ISCED 5A (Field of Education: 72)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Principali aree di competenza ricoperte                                    | Durante la Specializzazione:<br>Dal 01 Maggio 2011 al 30 Settembre 2011 presso il Bristol Haematology and Oncology Centre (BHOC), University Hospitals Bristol: Specializzando in Oncologia Medica (Status Observer nell'ambito dei Tumori Gastrointestinali e Tumori Cerebrali con Dr S. Falk e Dr K. Hopkins). Attività: Gestione clinica dei pazienti con tumori cerebrali e gastrointestinali. Partecipazione in tumor board multidisciplinari presso BHOC, Frenchay Hospital e SouthMead Hospital. Ricerca clinica nel campo dei tumori gastrointestinali.<br>Dal 01 Maggio 2010 a Giugno 2010 presso Unità dei Tumori della Testa e del Collo (diretta dalla Prof. Lisa Licitra) della Fondazione IRCCS Istituto Nazionale dei Tumori, Milano: Specializzando in Oncologia Medica. Attività: Assistenza clinica e attività di Ricerca clinica nell'ambito dei Tumori maligni della testa e del collo. |
| Data                                                                       | Luglio 2007                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Titolo conseguito                                                          | Abilitazione all'esercizio della Professione Medica                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Nome e tipo di organizzazione presso la quale è stato conseguito il titolo | Università degli Studi "Federico II" di Napoli, Italia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Livello in classificazione nazionale o internazionale                      | ISCED 5A (Field of Education: 72)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Data                                                                       | 16 Gennaio 2007                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Titolo conseguito                                                          | Laurea in Medicina e Chirurgia (cum laude)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Nome e tipo di organizzazione presso la quale è stato conseguito il titolo | Università degli Studi "Federico II" di Napoli, Italia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Livello in classificazione nazionale o internazionale                      | ISCED 5A (Field of Education: 72)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

|                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Principali aree di competenza ricoperte                                    | Dal 2005 al 2007 presso Università degli Studi "Federico II" di Naples, Dipartimento di Endocrinologia e Oncologia Molecolare e Clinica: Internato in Oncologia Medica.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Date (dal – al)                                                            | 1996 – 2000                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Titolo conseguito                                                          | Diploma di Maturità Classica (votazione: 100/100)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Nome e tipo di organizzazione presso la quale è stato conseguito il titolo | Liceo Classico "D. Cirillo", Aversa (CE), Italia                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Livello in classificazione nazionale o internazionale                      | ISCED 5A (Field of Education: 72)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Attività personali e competenze</b>                                     |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lingua Madre                                                               | Italiana                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Altre Lingue                                                               | Inglese                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Livello di auto-valutazione europeo* (per Lingua Inglese)                  | Comprensione: (C2)<br>Linguaggio parlato: (C1)<br>Scrittura: (C2)<br><br>(*) <i>Common European Framework of Reference for Languages</i>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Altre attività/competenze                                                  | Abilità a usare i più comuni programmi informatici (es. Microsoft Programs and Macintosh Pages)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Informazioni aggiuntive</b>                                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|                                                                            | <p>Sub-Investigator di diversi studi clinici Italiani e Internazionali mirati alla gestione dei pazienti con tumori maligni della testa e del collo. Esperienza certificata nella gestione degli studi clinici (più recente GCP R2 Training Certificate è datato 3/Ottobre/2017).</p> <p>Certificazione nelle Tecniche di Supporto Avanzato (ALS) (più recente ALS Training Certificate è datato 3/Maggio/2018).</p> <p>Certificazione di ESMO E-Module "Prognostic and Predictive Biomarkers in Head &amp; Neck Cancer" ottenuta nel 2016; CME-accreditata, per la Società Europea di Oncologia Medica (ESMO) nell'ambito del progetto di E-V-Learning.</p> <p>Professore a Contratto del Corso di Laurea in Scienze Infermieristiche (Corso di Medicina Interna) negli anni accademici 2016-2017; 2017-2018; 2018-2019.</p> <p>Membro delle seguenti società scientifiche/professionali: ESMO (European Society for Medical Oncology); AIOM (Associazione Italiana di Oncologia Medica). Ad Ottobre 2017 (per biennio 2017-19) eletto come Membro del Working Group (WG) AIOM giovani.</p> <p>Premiato come miglior poster nel 2015 presso AIOM Meeting per abstract dal titolo "Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area" presentato da Alfieri S. et al. Annals of Oncology 2015, 26 (Supplement 6): vi 67-vi 68, 2015.</p> <p>Svolgimento del "Multidisciplinary Preceptorship Course in Head and Neck Cancer", anni: 2014, 2015, 2016.</p> <p>H-Index (secondo Scopus, Web of Science) = 9 (al 01/Agosto/2019).</p> <p>Numero totale di citazioni = 340 (al 01/Agosto/2019).</p> <p>Numero totale di pubblicazioni accettate = 40, come <i>first</i> o <i>co-first</i> author: 11; come second author: 1; come <i>last</i> or <i>co-last</i> author: 4. Articoli già sottomessi: 1 (al 01/Agosto/2019).</p> |
| Publicazioni scientifiche                                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |



- Bossi P, Peris K, Calzavara-Pinton P, Queirolo P, Alfieri S, Palla M, Rossi MT, Spagnolo F, Tambone S, Astolfi C, Ascierto PA. Cohort analysis of safety and efficacy of vismodegib in Italian patients enrolled in the phase II, multicentre STEVIE study. *Submitted to Journal of the European Academy of Dermatology and Venereology Office.*
1. Locati LD, Cavalieri S, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. *Head Neck*. 2019 Jul 29. doi: 10.1002/hed.25891.
  2. Imbimbo M\*, Alfieri S\*, Botta L, Bergamini C, Gloghini A, Calareso G, Orlandi E, Iacovelli NA, Guzzo M, Granata R, Resteghini C, Locati L, Volpi CC, Licitra L, Bossi P. Surveillance of Patients with Head and Neck Cancer with an Intensive Clinical and Radiologic Follow-up. *Otolaryngol Head Neck Surg*. 2019 Jul 9:194599819860808. doi: 10.1177/0194599819860808.
  3. Cavalieri S, Perrone F, Milione M, Bianco A, Alfieri S, Locati LD, Bergamini C, Resteghini C, Galbiati D, Platini F, Licitra L, Bossi P. PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. *Oncology*. 2019;97(2):112-118. doi: 10.1159/000500246. Epub 2019 May 21.
  4. Bossi P, Giusti R, Tarsitano A, Airolidi M, De Sanctis V, Caspiani O, Alterio D, Tartaro T, Alfieri S, Siano M. The point of pain in head and neck cancer. *Critical Reviews in Oncology/Hematology*. April 2019. [Epub ahead of print]; doi: 10.1016/j.critrevonc.2019.04.001.
  5. Bossi P\*, Alfieri S\*, Stojan P, Takes RP, Lopez F, Makitie A, Saba N, Tapia JPR, Bradford CR, Suarez C, Zafereo M, Forastiere AA, Vermorken JB, Quer M, Sanabria A, Simo R, De Bree R, Rinaldo A, Ferlito A. Prognostic and predictive factors in recurrent and/or metastatic head and neck squamous cell carcinoma: A review of the literature. *Critical Reviews in Oncology/Hematology*. 137, February 2019. doi: 10.1016/j.critrevonc.2019.01.018.
  6. Cavalieri S, Platini F, Bergamini C, Resteghini C, Galbiati D, Bossi P, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? *Expert Opin Investig Drugs*. 2019 Mar 22:1-9. doi: 10.1080/13543784.2019.1598376. [Epub ahead of print].
  7. Grisanti S, Bianchi S, Locati LD, Triggiani L, Vecchio S, Bonetta A, Bergamini C, Conte P, Airolidi M, Merlano M, Carlini P, Ibrahim T, Rossetto C, Alfieri S, Pronzato P, Tonoli S, Maroldi R, Nicolai P, Resteghini C, Magrini SM, Berruti A. Bone metastases from head and neck malignancies: Prognostic factors and skeletal-related events. *PLoS One*. 2019 Mar 20;14(3):e0213934. doi: 10.1371/journal.pone.0213934. eCollection 2019.
  8. Siano M\*, Alfieri S\*, Granata R, Calareso G, Orlandi E, Bergamini C, Locati LD. The dilemma of metastatic medullary thyroid carcinoma: when to start systemic treatment. *Tumori*. 2019 Feb 19:300891619829571. doi: 10.1177/0300891619829571. [Epub ahead of print].
  9. Bossi P, Di Pede P, Guglielmo M, Granata R, Alfieri S, Iacovelli NA, Orlandi E, Guzzo M, Bianchi R, Ferella L, Infante G, Miceli R, Licitra L, Ripamonti CI. Prevalence of Fatigue in Head and Neck Cancer Survivors. *Ann Otol Rhinol Laryngol*. 2019 Jan 30:3489419826138. doi: 10.1177/0003489419826138. [Epub ahead of print].
  10. Alessi A, Lorenzoni A, Cavallo A, Padovano B, Iacovelli NA, Bossi P, Alfieri S, Serafini G, Colombo CB, Cicchetti A, Mira M, Licitra L, Fallai C, Crippa F, Orlandi E. Role of pretreatment 18F-FDG PET/CT parameters in predicting outcome of non-endemic EBV DNA-related nasopharyngeal cancer (NPC) patients treated with IMRT and chemotherapy. *Radiol Med*. 2018 Dec 17. doi: 10.1007/s11547-018-0980-6. [Epub ahead of print].



11. Cappelletti V, Miodini P, Reduzzi C, Alfieri S, Daidone MG, Licitra L, Locati LD. Tailoring treatment of salivary duct carcinoma (SDC) by liquid biopsy: ARV7 expression in circulating tumor cells. *Ann Oncol*. 2018 Jul 1;29(7):1598-1600. doi: 10.1093/annonc/ndy141.
12. Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. *Eur J Cancer*. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004. Epub 2018 May 4.
13. Resteghini C, Perrone F, Miceli R, Bergamini C, Alfieri S, Orlandi E, Guzzo M, Granata R, Galbiati D, Cavalieri S, Locati L, Licitra L, Bossi P. Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. *Tumori*. 2018 Jun;104(3):213-220. doi: 10.1177/0300891618765558. Epub 2018 Apr 18.
14. Cavalieri S, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. *Expert Opin Drug Metab Toxicol*. 2018 Apr;14(4):379-385. doi: 10.1080/17425255.2018.1461839. Epub 2018 Apr 13.
15. Orlandi E\*, Alfieri S\*, Simon C, Trama A, Licitra L; RARECAREnet Working Group. Treatment challenges in and outside a network setting: Head and neck cancers. *Eur J Surg Oncol*. 2019 Jan;45(1):40-45. doi: 10.1016/j.ejso.2018.02.007. Epub 2018 Feb 14.
16. Alfieri S, Cavalieri S, Licitra L. Immunotherapy for recurrent/metastatic head and neck cancer. *Curr Opin Otolaryngol Head Neck Surg*. 2018 Apr;26(2):152-156. doi: 10.1097/MOO.0000000000000448.
17. Alfieri S, Bergamini C, Granata R, Locati L, Licitra L, Bossi P. Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience. *Target Oncol*. 2018 Apr;13(2):253-256. doi: 10.1007/s11523-017-0545-y.
18. Resteghini C, Alfieri S, Quattrone P, Dominoni F, Garzone G, Orlandi E, Locati L, Bergamini C, Galbiati D, Iacovelli NA, Fallai C, Licitra L, Bossi P. RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target? *Oncotarget*. 2017 Oct 16;8(56):96184-96189. doi: 10.18632/oncotarget.21856. eCollection 2017 Nov 10.
19. Alfieri S, Orlandi E, Bossi P. The Case Volume Issue in Head and Neck Oncology. *Curr Treat Options Oncol*. 2017 Oct 27;18(11):65. doi: 10.1007/s11864-017-0507-8.
20. Volpi CC, Ciniselli CM, Gualeni AV, Plebani M, Alfieri S, Verderio P, Locati L, Perrone F, Quattrone P, Carbone A, Pilotti S, Gloghini A. In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating. *Hum Pathol*. 2018 Apr;74:32-42. doi: 10.1016/j.humpath.2017.09.011. Epub 2017 Oct 6.
21. Resteghini C, Cavalieri S, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L, Locati LD. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. *Best Pract Res Clin Endocrinol Metab*. 2017 Jun;31(3):349-361. doi: 10.1016/j.beem.2017.04.012. Epub 2017 May 10.
22. Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Noiè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. *Ann Oncol*. 2017 Oct 1;28(10):2547-2551. doi: 10.1093/annonc/mdx315.
23. Meregaglia M, Cairns J, Alfieri S, Favales F, Mazzitelli D, Orlandi E, Licitra L, Bossi P. Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. *Value Health*. 2017 Jun;20(6):799-808. doi: 10.1016/j.jval.2017.01.012. Epub 2017 Mar 31.



24. Alfieri S, Iacovelli NA, Marcegaglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, Locati L, Licitra L, Bossi P. Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area. *Oncotarget*. 2017 Jul 18;8(29):47780-47789. doi: 10.18632/oncotarget.17822.
25. Siano M, Infante G, Resteghini C, Cau MC, Alfieri S, Bergamini C, Granata R, Miceli R, Locati L, Licitra L, Bossi P. Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy. *Oral Oncol*. 2017 Jun;69:33-37. doi: 10.1016/j.oraloncology.2017.04.002. Epub 2017 Apr 9.
26. Tonella L, Giannoccaro M, Alfieri S, Canevari S, De Cecco L. Gene Expression Signatures for Head and Neck Cancer Patient Stratification: Are Results Ready for Clinical Application? *Curr Treat Options Oncol*. 2017 May;18(5):32. doi: 10.1007/s11864-017-0472-2.
27. Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF, Locati LD. Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm? *Oral Oncol*. 2017 Mar;66:58-63. doi: 10.1016/j.oraloncology.2016.12.016. Epub 2017 Jan 19.
28. Iacovelli NA, Naimo S, Bonfantini F, Cavallo A, Bossi P, Fallai C, Pignoli E, Alfieri S, Bergamini C, Favale F, Orlandi E. Preemptive treatment with Xonrid®, a medical device to reduce radiation induced dermatitis in head and neck cancer patients receiving curative treatment: a pilot study. *Support Care Cancer*. 2017 Jun;25(6):1787-1795. doi: 10.1007/s00520-017-3569-z. Epub 2017 Jan 20.
29. Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, Civelli E, Morosi C, Lo Vullo S, Imbimbo M, Quattrone P, Dagrada GP, Granata R, Resteghini C, Mirabile A, Alfieri S, Orlandi E, Mariani L, Saibene G, Pilotti S, Licitra L. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. *Eur J Cancer*. 2016 Dec;69:158-165. doi: 10.1016/j.ejca.2016.09.022. Epub 2016 Nov 5.
30. Pala L, Bergamini C, Imbimbo M, Granata R, Locati L, Alfieri S, Licitra L, Bossi P. Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report. *Tumori*. 2016 Nov 11;102(Suppl. 2). doi: 10.5301/tj.5000485.
31. Bossi P, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, Locati L, Alfieri S, Imbimbo M, Granata R, Mariani L, Iacovelli NA, Huber V, Cavallo A, Licitra L, Rivoltini L. Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. *Int J Radiat Oncol Biol Phys*. 2016 Dec 1;96(5):959-966. doi: 10.1016/j.ijrobp.2016.08.047. Epub 2016 Sep 6.
32. Bossi P, Alfieri S. The Benefit of a Multidisciplinary Approach to the Patient Treated with (Chemo) Radiation for Head and Neck Cancer. *Curr Treat Options Oncol*. 2016 Oct;17(10):53. doi: 10.1007/s11864-016-0431-3.
33. Bossi P, Alfieri S. Investigational drugs for head and neck cancer. *Expert Opin Investig Drugs*. 2016 Jul;25(7):797-810. doi: 10.1080/13543784.2016.1175435. Epub 2016 Apr 25.
34. Cocorocchio E, Gandini S, Alfieri S, Battaglia A, Pennacchioli E, Tosti G, Spadola G, Barberis M, Leo MD, Riviello C, Pala L, Intelisano A, Martinoli C, Ferrucci PF. Dabrafenib in metastatic melanoma: a monocentric 'real life' experience. *Ecancermedicalscience*. 2016 Mar 3;10:624. doi: 10.3332/ecancer.2016.624.
35. Alfieri S, Ripamonti CI, Marcegaglia S, Orlandi E, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, Licitra L, Bossi P. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. *Head Neck*. 2016 Apr;38 Suppl 1:E1521-7. doi: 10.1002/hed.24272. Epub 2016 Feb 5.



36. Bergamini C, Locati L, Bossi P, Granata R, Alfieri S, Resteghini C, Imbimbo M, Fallai C, Orlandi E, Tana S, Iacovelli NA, Guzzo M, Ibba T, Colombo S, Bianchi R, Pizzi N, Fontanella W, Licitra L. Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer? *Oral Oncol*. 2016 Mar;54:54-7. doi: 10.1016/j.oraloncology.2016.01.001. Epub 2016 Jan 13.
37. Ciccarese C\*, Alfieri S\*, Santoni M, Santini D, Brunelli M, Bergamini C, Licitra L, Montironi R, Tortora G, Massari F. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. *Expert Opin Drug Metab Toxicol*. 2016;12(1):57-75. doi: 10.1517/17425255.2016.1120287. Epub 2015 Dec 8.
38. Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, Cappellini GC, De Galitis F, Marchetti P, Amato G, Lazzeri A, Pala L, Coccorocchio E, Martinoli C. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. *Br J Cancer*. 2015 Jun 9;112(12):1904-10. doi: 10.1038/bjc.2015.180. Epub 2015 May 26.
39. Massari F, Santoni M, Ciccarese C, Santini D, Alfieri S, Martignoni G, Brunelli M, Piva F, Berardi R, Montironi R, Porta C, Cascinu S, Tortora G. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. *Cancer Treat Rev*. 2015 Feb;41(2):114-21. doi: 10.1016/j.ctrv.2014.12.013. Epub 2015 Jan 6.
40. Colantuoni M, Matano E, Alfieri S, De Placido S, Carlomagno C. Guillain-Barre Syndrome Associated with Gastric Cancer: Paraneoplastic Syndrome or Immunological Disorder? *World J Oncol*. 2010 Dec;1(6):247-249. doi: 10.4021/wjon259w. Epub 2011 Jan 1.

#### Abstract (Inglese):

Hyperprogressive disease (HPD) in head and neck squamous cell carcinoma (HNSCC) patients treated with immune checkpoint inhibitors (ICI). Salvatore Alfieri, Roberto Ferrara, Giuseppina Calareso, Stefano Cavalieri, Francesca Platini, Moela Mancinelli, Carlo Resteghini, Ester Orlandi, Nicola Alessandro Iacovelli, Letizia Ferella, Cesare Piazza, Giulia Apollonio, Donata Galbiati, Paolo Bossi, Cristiana Bergamini, Laura Deborah Locati, Lisa F. Licitra. Accepted for *POSTER SESSION* at the ASCO (American Society of Clinical Oncology) Annual Meeting 2019. Abstract#260473.

Clinical Prognostic Factors in patients with recurrent or metastatic carcinoma of the head and neck treated with immunotherapy. Carlo Resteghini, Stefano Cavalieri, Alessandro Rametta, Salvatore Alfieri, Donata Galbiati, Francesca Platini, Laura Deborah Locati, Paolo Bossi, Cristiana Bergamini, Roberta Granata, Ester Orlandi, Cesare Piazza, Moela Mancinelli, Lisa F. Licitra. Accepted as *publication only* at the ASCO (American Society of Clinical Oncology) Annual Meeting 2019. Abstract#260325.

Retrospective analysis of baseline clinical factors associated to CDDP-nephrotoxicity in locally advanced head and neck cancer (LAHNC) patients. Francesca Platini, Francesco Barretta, Salvatore Alfieri, Stefano Cavalieri, Carlo Resteghini, Donata Galbiati, Laura Deborah Locati, Cristiana Bergamini, Roberta Granata, Giuseppina Calareso, Nicola Alessandro Iacovelli, Pasquale Quattrone, Fabiola Incandela, Paolo Bossi, Lisa F. Licitra. Accepted as *publication only* at the ASCO (American Society of Clinical Oncology) Annual Meeting 2019. Abstract#263813.

Druggable molecular targets in skin adnexal malignancies. Stefano Cavalieri, Federica Perrone, Pasquale Quattrone, Laura Locati, Cristiana Bergamini, Roberta Granata, Salvatore Alfieri, Carlo Resteghini, Donata Galbiati, Francesca Platini, Giuseppina Calareso, Lisa F. Licitra, Paolo Bossi. *Journal of Clinical Oncology* (15\_suppl):e21619-e21619. May 2018.

Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aerodigestive tract (NCT02860936). Laura Locati, Donata Galbiati, Giuseppina Calareso, Salvatore Alfieri, Roberta Granata, Paolo Bossi, Cristiana Bergamini, Carlo Resteghini, Stefano Cavalieri, Francesca Platini, Pasquale Quattrone, Moela Mancinelli, Andrea Zucchella, Luigi Mariani, Guido Fedele, Lisa F. Licitra. *Journal of Clinical Oncology* 36(15\_suppl):6086-6086. May 2018.



Diagnostic workup of Cervical Unknown Primary (CUP) of the head and neck (HN). Bergamini C, Locati L, Bossi P, Orlandi E, Piazza C, Granata R, Alfieri S, Resteghini C, Cavalieri S, Platini F, Licitra L. Tumori Journal 2018, Vol. 104(4S) 6-224, L11.

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Galbiati D, Cavalieri S, Alfieri S, Resteghini C, Bergamini C, Granata R, Platini F, Locati LD, Licitra L and Bossi P. Tumori Journal 2018, Vol. 104(4S) 6-224, L02.

Recommendations for an appropriate clinical use of circulating EBV-DNA in nasopharyngeal carcinoma: comprehensive clinical practice guidelines evaluation. Trevisiol C, Vaona A, Fabrizio A.S., Gion M., Taverna F., Mazzocchi A, Licitra L., Alfieri S and Bossi P. Tumori Journal 2018, Vol. 104(4S) 6-224, L03.

Subsite-dependent prognostic impact of age in patients with nasopharyngeal and oropharyngeal cancer. R Granata, E Orlandi, G Infante, N A Iacovelli, R Miceli, A Cavallo, S Alfieri, C Bergamini, C Resteghini, D Galbiati, S Cavalieri, L Locati, S Tana, S Naimo, C Fallai, L Licitra, P Bossi. Annals of Oncology - 28(suppl\_6), 2017.

A single institution twenty-year experience of recurrent or metastatic epithelial non glandular sinonasal cancer. S Cavalieri, R Granata, L Locati, C Bergamini, S Alfieri, C Resteghini, D Galbiati, E Orlandi, N A Iacovelli, G Calareso, M Guzzo, P Quattrone, L Licitra, P Bossi. Annals of Oncology - 28(suppl\_6), 2017.

Gene-expression profiles of primary and metastatic lesions in head and neck squamous cell carcinoma. S Alfieri, P Bossi, D Galbiati, M Giannoccaro, S Pilotti, F Perrone, N Paielli, L Tonella, C Bergamini, R Granata, C Resteghini, S Cavalieri, N A Iacovelli, E Orlandi, L D Locati, L Licitra, S Canevari, L De Cecco. Annals of Oncology - 28(suppl\_6), 2017.

A phase II trial of dacomitinib in locally advanced unresectable or metastatic skin squamous cell carcinoma. P Bossi, S Cavalieri, F Perrone, R Miceli, P Ascierto, L Locati, C Bergamini, R Granata, S Alfieri, C Resteghini, D Galbiati, A Busico, N Paielli, R Patuzzo, A Maurichi, G Gallino, R Ruggeri, L Mariani, M Palla, L Licitra. Annals of Oncology - 28(suppl\_6), 2017.

Association Between Toxicity Profiles During Radiation Therapy (RT) for Oropharyngeal Cancer and CBCT-Derived and Dosimetric Factors to Evaluate Global Toxicity During RT for Oropharyngeal Cancer. Facchinetti N, Cavallo A, Cicchetti A, Iacovelli NA, Frasca S, Naimo S, Alfieri S, Bergamini C, Locati L, Licitra L, Pignoli E, Orlandi E. International Journal of Radiation Oncology Biology Physics 99(2):E657, 2017.

Sinonasal non glandular cancers relapsing after multimodal treatments. S. Cavalieri, R. Granata, L.D. Locati, C. Bergamini, S. Alfieri, C. Resteghini, D. Galbiati, E. Orlandi, N.A. Iacovelli, G. Calareso, M. Guzzo, P. Quattrone, L. Licitra, P. Bossi. Annals of Oncology (2017) 28 (suppl\_5): v372-v394.

Nasopharyngeal Carcinoma: prognostic factors analysis in patients treated with IMRT and chemotherapy. N.A. Iacovelli, A. Cavallo, E. De Ponti, P. Bossi, S. Alfieri, G. Rossi, S. Naimo, C. Bergamini, S. Tana, L. Licitra, E. Pignoli, C. Fallai, E. Orlandi. Radiotherapy and Oncology 119:S518 EP-1078.

Retreatment with Vismodegib is active in progressive advanced Basal Cell Carcinoma: first report from a single-Institution experience. S. Alfieri, P. Bossi, R. Granata, C. Bergamini, C. Resteghini, D. Galbiati, L. Locati, L. Licitra. Annals of Oncology - 27 (Supplement 4): 2016, M05.

Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study. C. Bergamini, D. Cortinovis, S. Fatigoni, M. Cossu Rocca, A. Fabi, A. Iannace, A. Emiliani, M.A. Pessi, C.I. Ripamonti, S. Alfieri, R. Granata, F. Agustoni, P. Bidoli, F. Roila, F. Nolè, F. Macchi, L. Michellini, F. Montanaro, P. Bossi. Annals of Oncology – Volume 27 (Supplement 4), iv 57, 2016.

Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer: a single center experience. R. Granata, P. Bossi, C. Bergamini, S. Alfieri, C. Resteghini, D. Galbiati, E. Orlandi, N.A. Iacovelli, C. Fallai, M. Guzzo, G. Infante, L. Locati, R. Miceli, L. Mariani, L. Licitra. Annals of Oncology - Volume 27 (Supplement 4), iv85-iv88, 2016.



**RANK expression in EBV associated nasopharyngeal cancer metastasis in non-endemic setting: a possible immunologic pathway to be targeted?**

C. Resteghini, S. Alfieri, P. Quattrone, F. Dominoni, G. Garzone, E. Orlandi, L. Locati, C. Bergamini, D. Galbiati, N.A. Iacovelli, L. Licitra, P. Bossi. *Annals of Oncology* - Volume 27 (Supplement 4), iv85-iv88, L04, 2016.

**Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients.** C. Villa, M. Meregaglia, C. Rognogni, P. Pistillo, E. Orlandi, A. Iacovelli, R. Granata, S. Alfieri, C. Bergamini, C. Resteghini, L. Locati, P. Bossi, M. Guzzo, L. Licitra, F. Favales. *Annals of Oncology* - Volume 27 (Supplement 4), iv85-iv88, L09, 2016.

**An added value to Multidisciplinary Team: does a Tutor help to manage head and neck cancer patients?** P. Cassini, S. Alfieri, P. Bossi, C. Bergamini, R. Granata, C. Resteghini, D. Galbiati, N.A. Iacovelli, E. Orlandi, F. Favales, C. Villa, P. Pistillo, L. Locati, L. Licitra. *Annals of Oncology* - Volume 27 (Supplement 4), iv85-iv88, L10, 2016.

**Analysis of patients' preferences for post-treatment clinical follow-up in head and neck cancers.** P. Pistillo, F. Favales, C. Villa, S. Alfieri, P. Bossi. *Annals of Oncology* - Volume 27 (Supplement 4):iv86-iv86. L06, 2016.

**Detecting characteristics of nodal invasion in advanced squamocellular oral cavity cancer through a gene expression profile on primary tumor.** De Cecco L, Perrone F, Cortelazzi B, Alfieri S, Pala L, Locati L, Giannoccaro M, Pilotti S, Canevari S, Licitra L, Bossi P. *Journal of Clinical Oncology* 33 (15\_suppl): 6062-6062, May 2015.

**Treatment-associated mortality in head and neck cancer receiving chemotherapy and radiation: Meta-analysis of published trials.**

P Bossi, C Resteghini, M Cinquini, C Bergamini, E Orlandi, L.D. Locati, R Granata, S Alfieri, N.A. Iacovelli, C Fallai, L.F. Licitra. *Journal of Clinical Oncology* 33(15\_suppl):6062-6062, May 2015.

**Circulating pretreatment Epstein Barr Virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area.** S. Alfieri, C. Resteghini, L. Pala, S. Marcegaglia, N. A. Iacovelli, E. Orlandi, A. Gloghini, G.P. Gesu, D. Fanti, S. Racca, R. Dvir, D. Morelli, F. Taverna, P. Quattrone, C. Bergamini, R. Granata, M.C. Cau, L.D. Locati, L.F. Licitra and P. Bossi. *Journal of Clinical Oncology*, 2015 ASCO Annual Meeting (May 29 - June 2, 2015). Vol 33, No 15 suppl (May 20 Supplement), 2015: e17054.

**Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer.** P. Bossi, E Orlandi, R Granata, P Quattrone, P Battaglia, D Lombardi, L Pala, M Barbara, P Nicolai, P Castelnuovo, M Guzzo, L Locati, C Resteghini, S. Alfieri, M Imbimbo, NA Iacovelli, G Calareso, C Bergamini, L Licitra. *Annals of Oncology* 2015, 26 (Supplement 6): vi 68, 2015.

**Site of metastatic disease influence adenoid cystic cancer (ACC) patient's outcome.** MC Cau, S. Alfieri, S Lo Vullo, C Bergamini, P Bossi, C Resteghini, M Imbimbo, M Siano, R Granata, L Licitra, L Locati. *Annals of Oncology* 2015, 26 (Supplement 6): vi 68, 2015.

**Outcome of systemic treatments after first line platinum and cetuximab treatment in patients with recurrent/metastatic (RM) head and neck squamous cell cancer (HNSCC): a retrospective study.** C Resteghini, M Siano, MC Cau, S. Alfieri, C Bergamini, R Granata, R Miceli, G Infante, N Imbimbo, L Locati, L Licitra, P Bossi. *Annals of Oncology* 2015, 26 (Supplement 6): vi 70, 2015.

**Baseline neutrophil to lymphocyte ratio as a selection criterion for ipilimumab treatment in metastatic melanoma patients.** Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Pala L, Di Giacomo A, Antonini Cappellini G, Giannarelli D, Coccorocchio E, Martinoli C. August 2015. *Cancer Research* 75 (15 Supplement): LB-115-LB-115.

**Incidence of pneumonia in hospitalized head and neck cancer patients treated by chemoradiation.** Bergamini C, Bossi P, Granata R, Alfieri S, Imbimbo M, Pala L, Locati L, Resteghini C, Orlandi E, Iacovelli NA, Fallai C, Licitra L. Publication in the AIOM 2014 Congress Abstract Book, a supplement to the official AIOM journal *Annals of Oncology*.

**Up-regulation of RAS pathway could predict the risk of distant metastases in HPV+ oropharynx cancer.** L.D. Locati, L. De Cecco, F. Perrone, B. Cortelazzi, A. Gloghini, C. Volpi, S. Pilotti, R. Granata, P. Bossi, E. Orlandi, C. Resteghini, S. Alfieri, C. Bergamini, M. C. Cau, M. Imbimbo, P. Quattrone, S. Canevari, L.F. Licitra. Publication in the AIOM 2014 Congress Abstract Book, a supplement to the official AIOM journal *Annals of Oncology*.

Opioids – base therapy for oral mucositis (OM) – related pain during curative chemoradiotherapy (CT – RT) in oropharyngeal cancer (OPC) patients. Alfieri S, Ripamonti C, Marcegaglia S, Granata R, Iacovelli NA, Orlandi E, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati L, Licitra L, Bossi P. Publication in the AIOM 2014 Congress Abstract Book, a supplement to the official AIOM journal Annals of Oncology.

Skin lesions: unusual presentation of gastric cancer. Salvatore Alfieri, Chiara Carlomagno, Maria Colantuoni, Alfonso De Stefano, Lucia Cannella, Chiara Alessandra Cella, Sabino De Placido. Educational Cancer Convention Lugano-ECCLU, 2-4 luglio 2009, Lugano, Svizzera.

Multiple primary malignant neoplasms and familiar anamnesis. Maria Colantuoni, Chiara Carlomagno, Lucia Cannella, Salvatore Alfieri, Alfonso De Stefano, Chiara Alessandra Cella, Sabino De Placido. Educational Cancer Convention Lugano-ECCLU, 2-4 luglio 2009, Lugano, Svizzera.

Double complete response in MCRC patient. Alfonso De Stefano, Chiara Carlomagno, Lucia Cannella, Salvatore Alfieri, Maria Colantuoni, Chiara Alessandra Cella, Sabino De Placido. Educational Cancer Convention Lugano-ECCLU, 2-4 luglio 2009, Lugano, Svizzera.

Surgery in lung colon cancer metastasis. Chiara Carlomagno, Chiara Alessandra Cella, Alfonso De Stefano, Lucia Cannella, Salvatore Alfieri, Maria Colantuoni, Sabino De Placido. Educational Cancer Convention Lugano-ECCLU, 2-4 luglio 2009, Lugano, Svizzera.

Bevacizumab as 4th line treatment in metastatic colorectal cancer. Lucia Cannella, Chiara Carlomagno, Alfonso De Stefano, Salvatore Alfieri, Maria Colantuoni, Chiara Alessandra Cella, Sabino De Placido. Educational Cancer Convention Lugano-ECCLU, 2-4 luglio 2009, Lugano, Svizzera.

#### Abstract (Italiano):

Carcinoma del rinofaringe: analisi dei fattori prognostici in una casistica di 149 pazienti consecutivi, trattati con tecniche di radioterapia ad intensità modulata e chemioterapia. Ester Orlandi, Nicola Alessandro Iacovelli, Paolo Bossi, Elena DE Ponti, Salvatore Alfieri, Mauro Carrara, Tommaso Giandini, Francesca Bassani, Roberta Granata, Cristiana Bergamini, Laura Locati, Marco Guzzo, Lisa Licitra, Emanuela Pignoli, Gianstefano Gardani, Carlo Fallai. AIRO 2014; abstract N. 0211.

#### Libri scritti (Inglese):

ESMO Head and Neck Cancers – Essentials for Clinicians

Edited by Lisa Licitra, Michalis V Karamouzis, Michele Ghielmini on behalf of ESMO (European Society of Medical Oncology)

Site and Stage-driven treatment strategy in non-metastatic disease – by L Licitra, S Alfieri & M Imbimbo

Pages: 19-23

A.A.V.V. Editor: ESMO.

ESMO Hand-Book of Immuno-Oncology

Edited by John B.A.G. Haanen, Raffaele Califano, Iwona Lugowska, Marina Chiara Garassino on behalf of ESMO (European Society of Medical Oncology)

Immunotherapy in Head and Neck Tumors (HPV+ and HPV-) – Immuno- oncology in Head and Neck Cancer: Predictive Biomarkers? – by Alfieri S et al.

Pages: 210-213

A.A.V.V. Editor: ESMO.

#### Libri scritti (Italiano):



**Il carcinoma adenoido-cistico nel distretto cervico-facciale**

Quaderni di aggiornamento dell'A.O.O.I. (Associazione Otorinolaringologi Ospedalieri Italiani) –

**Biologia, genetica e fattori prognostici:** M.C. Cau, S. Alfieri, C. Bergamini, E. Oriandi, L. Licitra, L.D. Locati.

Pages: 59-74.

A.A.V.V. Editor: TorGraf.

**Tumori della Testa e del collo – Volume 5**

Collana di Immuno-Oncologia di AIOM (Associazione Italiana Oncologia Medica)

Biomarcatori predittivi di risposta a immunoterapici

Pages: 69-76.

A.A.V.V. Editor: Il Pensiero Scientifico Editore.

**ATTUALI ORIENTAMENTI NEL TRATTAMENTO DEI TUMORI DELLA TIROIDE**

Quaderni di aggiornamento dell'A.O.O.I. (Associazione Otorinolaringologi Ospedalieri Italiani) –

**Nuove prospettive di cura nella terapia sistemica dei carcinomi della tiroide**

Platini F, Alfieri S, Bergamini C, Locati LD

A.A.V.V. Editor: in press.

**Studi Clinici in corso (condotti come Sub-Investigator):**

An open-label, multicenter, dose-escalation, phase Ia/Ib study to evaluate safety, pharmacokinetics, and therapeutic activity of RO6874281, an immunocytokine consisting of interleukin 2 variant (IL-2v) targeting fibroblast activation protein- $\alpha$  (FAP), as a single agent (PART A) or in combination with trastuzumab or cetuximab (PART C). Roche BP29842. Eudra CT: 2015-002251-97.

Phase II trial of abiraterone acetate in patients with relapsed and/or metastatic, castration resistant salivary gland cancers. EUDRACT N° 2014-001274-34.

A Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Cabozantinib (XL184) at 60 mg/Day Compared to 140 mg/Day in Progressive, Metastatic Medullary Thyroid. Cancer Patients, Exelixis 113,446. Protocol number: XL184-401

The CONFRONT Phase I – II Trial: Activation of Immune Response in patients with R-M Head and Neck Cancer. Multimodality immunotherapy with Avelumab, short course radiotherapy and Cyclophosphamide in Head and Neck cancer. EudraCT n. 2017-000353-39.

A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs). Intergroup Study (EORTC-1206-HNCG). (EudraCT number 2013-000314-38) (NCT01969578).

A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM". EORTC 1559 Upstream. Eudra CT: 2017-000086-74.

A Randomized Phase III study of pembrolizumab given concomitantly with chemoradiation and as maintenance therapy versus chemoradiation alone in subjects with locally advanced head and neck squamous cell carcinoma (KEYNOTE-412). IND NUMBER: 122,325. EudraCT NUMBER: 2016-003934-25.

Immunotherapy Followed By EGFR Inhibitor In Locally Advanced Or Metastatic Squamous Cell Cancer Of The Skin: Tackling Primary And Secondary Resistance. Short name: I-Tackle. EudraCT NUMBER: 2017-003765-10.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630). IND NUMBER: 134,760. EudraCT NUMBER: 2018-001974-76.

A phase 2 study of REGN 2810, a fully human monoclonal antibody to programmed death-1, in patients with advanced basal cell carcinoma who experienced progression of disease on hedgehog pathway inhibitor therapy, or were intolerant of prior hedgehog pathway inhibitor therapy. IND Number: 127100. EudraCT Number: 2016-003122-16.

A phase III, multicenter, randomized, double-blind, placebo controlled study of atezolizumab (anti-PD-1 antibody) as adjuvant therapy after definitive local therapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. Protocol number: WO40242. EUDRACT number: 2017-003302-40. Ind number: 135963.

A multicenter randomized trial to evaluate the efficacy of Fentanyl pectin nasal spray (FPNS) versus Physician Choice (PC) - Usual Care (UC), in reducing incidental predictable breakthrough pain (IP-BTP) at swallowing in patients with head and neck cancer undergoing radiotherapy. EudraCT number: 2015-005110-30.

A Prospective Observational Study for the Development and Validation of New Prognostic Models in Head and Neck Cancer Patients for Decision Support.

Head and neck cancer patients' preference: developing, validating and testing a multi-cultural questionnaire in different treatment settings. Priority HN1/2.

#### **Studi Clinici condotti e già conclusi (condotti come Sub-Investigator):**

Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination with Tremelimumab versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients. AstraZeneca. Eagle. Study Code D419LC00001.

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). AstraZeneca Kestrel D419LC00001. Study Code D4193C00002.

A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. AstraZeneca Scores D5660C00004. Eudra CT 2015-002525-19.

A Phase 1/2 Study of the Combination of Lirilumab (Anti-KIR) Plus Nivolumab (Anti-PD-1) or Lirilumab Plus Nivolumab and Ipilimumab in Advanced Refractory Solid Tumors. BMS CA223-001. EUDRACT Number 2016-001359-36.

A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (Lirilumab) Administered in Combination with Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors. Clinical Protocol CA223001.

An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab versus Extreme Study Regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). Clinical Protocol CA209651. IND Number: 125872. EUDRACT Number 2016-000725-39.

A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). EUDRACT Number 2016-001645-64.

A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. MSD Keynote 048. EudraCT NUMBER: 2014-003698-41.



A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer. MSD Keynote 040. EudraCT NUMBER: 2014-001749-26.

Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, surgery, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in operable patients. SINTART1. EudraCT Number: 2013-000075-33.

SINTART2. "Multidisciplinary approach for poor prognosis sinonasal tumors: Phase II study of chemotherapy, photon and heavy ion radiotherapy integration for more effective and less toxic treatment in inoperable patients".

Phase II Study: Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer. EUDRACT: 2011-002564 – 24.

Phase II study on Inlyta® (axitinib) in recurrent and/or metastatic salivary gland cancers (SGCs) of the upper aerodigestive tract. EUDRACT number: 2014-003227-21.

Efficacy and safety of single agent pan-HER inhibitor Dacomitinib in the treatment of locally advanced unresectable or metastatic squamous cell cancer of the skin or with clinical contraindication to surgery. EUDRACT N° 2014-002175-28.

A phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients with either differentiated or medullary thyroid cancer progressing after first line therapy. EORTC protocol 1209-EnTF. EudraCT number 2012-004295-19. NCT01788982.

A Single-Arm, Open-Label, Multicenter, Phase IIb Clinical Trial with NIVolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN) – NIVACTOR Study. EudraCT number: 2017-000562-30.

Phase II study on Lenvatinib in recurrent and/or metastatic adenoid cystic carcinomas (ACC) of the salivary glands of the upper aerodigestive tract. EUDRACT NUMBER: 2015-000693-35. (NCT02860936).

Clinical Protocol CA209141. An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN).

HPV positive oropharyngeal cancer: characterization of immunological and viral profiles, and their role in the response to treatment.

A randomized phase II study for tertiary prevention of squamocellular carcinoma of head and neck (SCCHN) with a dietary intervention.

A randomized, double-blind, placebo controlled, mono-centre phase II study to evaluate the efficacy of treatment with ginseng in reducing fatigue in patients treated for head and neck Cancer.

Trial "TPF oral cavity, Italian study". Phase II study of preoperative TPF chemotherapy in locally advanced resectable oral cavity squamous cell cancer in order to improve the rate of pathological complete response.

Trial Cet-INT. "Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer (Italian clinical trial, phase II)".

INTERCEPTOR TRIAL. "Induction chemotherapy followed by Cetuximab plus definitive radiotherapy versus radiation plus cisplatin".

A Retrospective Cohort Study of PD-L1 in Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN). D4193R00002".

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer. Trial E7080-G000-303.

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase III Study to Assess the Efficacy and Safety of Vandetanib (CAPRELSA™) 300 mg in Patients with Papillary or Poorly Differentiated Thyroid Cancer That is Either Locally Advanced or Metastatic Who Are Refractory or Unsuitable for Radioiodine (RAI) Therapy.

Phase II multicenter randomized, double blind, placebo controlled study assessing the efficacy of buparlisib (BKM120) plus paclitaxel vs. placebo plus paclitaxel in patients with platinum pre-treated recurrent or metastatic head and neck squamous cell carcinoma.

Trial Vismodegib. "A single arm, open-label, phase II, multicentrum study, to assess the safety of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma (BCC)".

An International, Randomized, Double-Blind, Two-Arm Study to Evaluate the Safety and Efficacy of Vandetanib 150 and 300 mg/day in Patients with Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma with Progressive or Symptomatic Disease. Trial D4200C00097.

#### **Studi Clinici Disegnati e in corso (come Principal Investigator):**

Genomic analysis of familiar clustering of nasopharyngeal carcinoma in non-endemic settings. (ONGOING and approved in 2018 by Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

Analisi dei profili di espressione genica delle lesioni primarie e metastatiche di pazienti affetti da tumore squamocellulare della testa e del collo. (In submission for publication and approved in 2019 by Ethical Committee of Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

#### **Convegni scientifici (Relatore):**

Outcomes and prognostic factors in patients treated with preoperative chemoradiation for locally advanced rectal cancer – NBT (North Bristol Trust) Colorectal AGM (Annual General Meeting), Frenchay Hospital, Bristol, UK, 01/Novembre/2011.

Melanoma: a complex genomic disease – Oncologia Medica IEO (Istituto Europeo di Oncologia), Milano, 12/Ottobre/2012.

Novità in tema di tumori testa-collo – Convegno Nazionale AIOM GIOVANI: 2014 News in Oncology, Perugia, San Martino in Campo – Alla posta dei Donini, 12/Luglio/2014.

Le applicazioni informatiche legate ai dispositivi di tipo mobile come innovativo strumento di comunicazione per il paziente con neoplasia testa-collo – IV Congresso Nazionale AIOCC (Associazione Italiana Oncologia Cervico-Cefalica), Genova, 21/Novembre/2014.

Studi innovativi sul controllo del dolore nella terapia di supporto alla disfagia nei tumori testa-collo in trattamento radio chemioterapico – Congresso NICSO (Network Italiano delle Terapie di Supporto), Torrevicchia Teatino (CH), 08/Maggio/2015.

Circulating pre-treatment Epstein Barr virus DNA quantification as a prognostic factor in nasopharyngeal cancer patients in a non endemic area – Seminar on Nasopharyngeal Cancer, Milano, 12/Novembre/2015.

Management Delle Complicanze Da Radio-Chemioterapia In Oncologia Cervico-Cefalica: tossicità da chemioterapia – VI Conferenza Italiana per lo Studio e la Ricerca delle Ulcere, Piaghe, Ferite e la Riparazione Tessutale (C.O.R.T.E.), Roma, 11/Marzo/2016.



Haematological disorders: anemia, neutropenia, thromboembolism and bleeding – Consensus conference sulla global care del paziente con tumore testa-collo ricorrente/metastatico. Milano, 05/Maggio/2016.

Mucosite Orale – Update sulla terapia di supporto. Grandangolo in Oncologia. Focus su Terapie di supporto. Bologna, 09/Maggio/2017.

European Reference Networks (ERN) per i tumori testa e collo – Congresso Nazionale AIOCC (Associazione Italiana Oncologia Cervico-Cefalica), Milano, 10/Novembre/2017.

Neoplasie della Testa e del collo: Highlights del 2017 – Oncologia Medica Universitaria Italiana: formazione, ricerca e assistenza. Riunione Nazionale C.O.M.U. (Collegio degli Oncologi Medici Universitari), Torino, 03/Febbraio/2018.

Supportive care and nutrition in the curative setting of head and neck cancer – European School of Oncology (ESO) University post-graduate course – Clinical Oncology: Head and Neck Cancers, Milano, 06/Febbraio/2018.

Trattamenti integrati: Tavola rotonda su carcinoma testa collo, carcinoma esofageo, carcinoma del retto – 8° Congresso nazionale di Oncologia Geriatrica Salentina, Lecce, 19/Maggio/2018.

Tumori del distretto Testa-Collo -- Immuno-Oncologia: il panorama attuale e le sfide cliniche presenti e future, Milano, Ospedale Niguarda, 02/Ottobre/2018.

Progetto RUA (Rational Use of Analgesics), Milan, 03/Ottobre/2018.

Neoplasie ORL e della tiroide – Sulle spalle dei giganti Treviglio –ASST Bergamo Ovest, Treviglio, 04/Ottobre/2018.

Terapia medica del carcinoma squamocellulare della cute – 57° Congresso Nazionale A.D.O.I. (Associazione Dermatologi-Venereologi Ospedalieri Italiani), Grosseto, 18/Ottobre/2018.

Update Testa-Collo – Meeting Post ESMO 2018, Padova, 07/Novembre/2018.

Inibitori multichinasici: selezione dei pazienti e gestione degli eventi avversi – 12° Congresso Associazione Italiana della Tiroide (XXXVI giornate italiane della tiroide), Catania, 24/Novembre/2018.

Supportive care and nutrition in the curative setting of head and neck cancer – European School of Oncology (ESO) University post-graduate course – Clinical Oncology: Head and Neck Cancers, Inveruno (VA), 03/Aprile/2019.

Immunotherapy of head and neck tumors - XIII International SVO Conference on head and neck cancer together with MSKCC and Mayo Clinic. Mestre (VE), Ospedale dell'Angelo, 22/Giugno/2019.

Tumore della Testa e del Collo: l'ultima frontiera. Immuno-Time – Il Tempo dell'immunoterapia nel trattamento dei tumori solidi. La Spezia, 26/Giugno/2019.

#### **Convegni Scientifici (Moderatore):**

La chemioterapia di induzione nei tumori della testa e del collo: novità e attuali indicazioni – 12° congresso nazionale AIOM Giovani, Perugia, 07/Luglio/2018.

Seconda Giornata del carcinoma della tiroide 2019 – Aspetti di Criticità e nuove frontiere. Milano, Ospedale San Luca, IRCCS Istituto Auxologico Italiano, 22/Febbraio/2019.

**Grant di ricerca vinti/finanziati:**

CALL: GenderNetPlus

*Titolo del Progetto: G-DEFINER – GENDER DIFFERENCE IN SIDE EFFECTS OF IMMUNOTHERAPY: A POSSIBLE CLUE TO OPTIMIZE CANCER TREATMENT*

*Ruolo: Co-autore*

*Argomento: Sex, Gender and Aging ; Sex, Gender and Health*

Questo progetto ha ricevuto il finanziamento nel 2019 nell'ambito del Programma di Ricerca e Innovazione "Horizon 2020" della Unione Europea. Grant agreement N. 741874.

CALL: Bando per la valorizzazione della Ricerca Istituzionale (BRI) 2018

*Titolo del Progetto: BUILDING PRELIMINARY DATA FROM RADIOMIC ANALYSIS TO PREDICT CANCER RECURRENCE IN EFFECTIVELY CURED HEAD AND NECK CANCER PATIENTS ACCRUED IN AN ONGOING PROSPECTIVE STUDY*

*Ruolo: Primo Autore*

*Argomento: Building preliminary data (proof of concept) for future clinical and preclinical research projects*

Questo progetto ha ricevuto il finanziamento (Fondi 5x1000 Ministero della Salute 2015) dalla Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italia. Grant agreement N. DI17/1SA (statement n. 511 del 21/Dicembre/2018).

*Io autorizzo al trattamento dei miei dati personali, secondo il regolamento previsto dalla Legge Italiana (196/2003).*

Salvatore Alfieri, MD

01/08/2019  
